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Figure 1. Down-regulation of HSPB7 in RCC.  
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Part I: Downregulation of the tumor suppressor HSPB7, involved in the p53-pathway, in renal cell carcinoma by 
hypermethylation 
 
Introduction 
 
   Renal cell carcinoma (RCC) accounts for approximately 2% of all cancers worldwide and its incidence has increased by 2–
3% in the last decade with higher in developed countries. However, the underlying mechanisms are largely unknown. For the 
advanced-stage patients, drugs for treatment are limited and the response rates are far from satisfaction. To better understand 
the molecular mechanisms of renal carcinogenesis and apply the information for the development of effective treatment and 
early diagnosis, we analyzed expression profile of renal cell carcinomas (RCCs) using microarray consisting of 27,648 cDNA 
or ESTs, and found a small heat shock protein, HSPB7, whose function in cancer is unknown, to be down-regulated in a great 
majority of human RCC samples. In this study, we attempted to address two key questions, (1) whether HSPB7 has the 
growth suppressive function and (2) how HSPB7 is down-regulated in RCCs. We here report for the first time that HSPB7 is 
likely to be a tumor suppressor which is frequently down-regulated by DNA methylation in RCCs and is involved in the p53 
pathway. 
 
Methods and result 
 
   We first confirmed down-regulation of HSPB7 in RCC by quantitative real-time PCR (qPCR) and immunohistochemical 
(IHC) experiments after the analysis of microarray data. qPCR result showed that HSPB7 mRNA expression was 
significantly down-regulated in 11 of 13 (85%) RCC tissues compared with the normal renal tissue (A, Figure 1), and in all 
of five RCC cell lines compared with normal HEK 293 and RPTEC cells (B, Figure 1). IHC analysis of a tissue array 
consisting of 11 pairs of human RCC sample revealed that the expression of HSPB7 was significantly higher in normal 
kidney tissues than that in RCC tissues (Table 1). We also detected HSPB7 expression mainly in the cytoplasm of normal 
renal tubular epithelial cells. To explore the expression patterns of HSPB7 in other normal tissues, we performed qPCR 
analysis using mRNAs isolated from 25 normal tissues. HSPB7 expression was detected ubiquitously in human tissues. 
  
 
 
 
   
 
 
 
 
Figure 3. Ectopic HSPB7 expression suppressed RCC cell growth. 
Figure 4. HSPB7 is regulated by p53. 
Figure 2. Epigenetic silencing of HSPB7 in RCC cell lines. 
  Then, bisulfite sequencing of a genomic region of HSPB7 detected DNA hypermethylation of some segments of HSPB7 in 
RCC cells (region 4 in Figure 2) and concordantly a demethylating agent, 5-Aza-2'-deoxycytidine treatment of cancer cells 
restored HSPB7 expression significantly. In addition, we performed exon sequencing of HSPB7 in these five RCC cell lines, 
but no mutation or deletion/insertion was detected. This data indicated that suppression of HSPB7 in RCC was caused 
probably by DNA hypermethylation.  
   
 
  To study the effect of HSPB7 expression on tumor growth, Caki-1 and ACHN cells were transfected with HSPB7 
expression vector, pCAGGSnHC-HSPB7-HA. Introduction of HSPB7 into these two cancer cell lines caused significant 
decrease in the number of colony, compared with corresponding mock-transfected controls (Figure 3). We also performed 
colony formation assay in other 3 RCC cell lines (Caki-2, A498, and 786-O) using the same vectors, and confirmed the 
similar growth-suppressive effects, implying that HSPB7 may function as a tumor suppressor gene.  
   
  To further elucidate the biological significance, 
we first investigated its possible involvement in 
the p53-pathway (Figure 4). We applied qPCR 
analysis to evaluate the expression of HSPB7 in 
NCI-H1299 (p53 null) cell lines with or without 
introduction of p53 using the adenovirus system. 
After the infection of Ad-p53, we observed 
induction of HSPB7 in a dose-dependent (A) and 
time-dependent manner (B), while no induction 
was observed in the control cells. Concordantly, 
DNA damage by adriamycin treatment induced 
HSPB7 expression in HCT116 cells with wild-
type p53, but not in HCT116 cells without wild-
type p53 (C and D), indicating that HSPB7 
expression is regulated by wild-type p53. To 
further investigate whether HSPB7 is directly 
regulated by p53, we screened three possible 
p53-binding sites indicated by the p53-binding 
site search software developed by us, but neither 
of these candidate sites was confirmed to be a 
direct p53-binding site. Although there might be another site(s) that p53 might bind to, we are unable to conclude whether 
HSPB7 is directly or indirectly regulated by p53, it is certain that HSPB7 expression can be inducible by wild-type p53.   
 
Conclusion 
 
   In conclusion, we carried out a genome-wide gene expression analysis and identified HSPB7 to be a candidate tumor 
suppressor gene in RCC. We confirmed down-regulation of this gene caused by DNA hypermethylation, its growth 
suppressive effect in RCC cell lines and its p53-dependent expression, indicating the important roles of HSPB7 in renal 
carcinogenesis. Our finding could contribute to better understanding of the novel function of HSPB7 in cancer. 
 
 
Part II: O-glycosylation and stabilization of HSPA5 by GALNT6  
 
Abstract 
We previously reported that overexpression of GALNT6 (polypeptide N-acetylgalactosaminyl transferase 6) which is a 
GalNAc-type (or mucin-type) O-glycosyltransferase, played a critical role in breast carcinogenesis. To further investigate the 
molecular function of GALNT6, we screened the substrates of GALNT6 through VVA (Vicia Villosa agglutinin) lectin 
(specific to GalNAc-Ser/Thr, called Tn-antigen) pull-down assay followed by mass spectrometry (MS) analysis. Here we 
report that HSPA5 (heat shock 70kDa protein 5 (also known as GRP78, glucose-regulated protein, 78kDa)) is a novel 
substrate of GALNT6. HSPA5 is highly expressed in cancers and involved in many cellular processes including in ER 
(endoplasmic reticulum) stress and autophagy, however whether O-glycosylation affects the function of HSPA5 and promote 
carcinogenesis is largely unknown. We found high expression level of exogenous HSPA5 drives Golgi-to-ER relocation of 
GALNT6 and they co-localize at ER in HeLa GALNT6 stable cells. We confirmed GALNT6 directly binds to and 
glycosylates HSPA5, and the ATPase domain of HSPA5 is important for their binding. During the process, GALNT6 itself is 
also auto-glycosylated. Six candidate O-glycosylation sites in HSPA5 were identified by mass spectrometry and four of them 
were located in the ATPase domain. Further study showed that GALNT6 stabilizes HSPA5 protein and mutation at one 
potential O-glycosylation site, T184A, affects the stability of HSPA5. Taken together, our findings imply that GALNT6 O-
glycosylates and stabilizes HSPA5 protein, which may prolong the oncogenic effects of HSPA5 in breast cancer. Meanwhile, 
overexpression of HSPA5 can drive Golgi-to-ER relocation of GALNT6. The result may trigger O-glycosylation of multiple 
substrates of GALNT6 at ER. Our study revealed a novel mechanism of how GALNT6 and HSPA5 cooperate together to 
promote mammary carcinogenesis. And the O-glycosylated form of HSPA5 may be a good target for breast cancer therapy. 
 
